ArticleTranslational andrology and urology2025
Caprini score is a poor model for predicting risk of thromboembolic events in patients undergoing urethroplasty.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Caprini score for venous thromboembolism risk assessment: A scoping review of applications, validation, and future directions.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
- Geriatric assessment-integrated prediction model for postoperative deep vein thrombosis in older adults undergoing transurethral resection of the prostate: retrospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venous thromboembolism (VTE) is a feared complication in the perioperative period. Patients undergoing urethroplasty are placed in high lithotomy for an extended period, which is known to increase venous stasis, thus possibly increasing VTE risk. Even then, rates of VTE in urethroplasty patients have been shown to be low. We sought to evaluate the applicability of the 2005 Caprini risk assessment module in predicting VTE risk for patients undergoing urethroplasty. Methods: We performed a retrospective cohort study of patients who underwent urethroplasty at our institution from 2019-2024. Ninety-day perioperative outcomes were collected, and patients who had thromboembolic events were isolated for reporting. Risk factors for VTE were quantified using the 2005 Caprini risk assessment model. Results: There were 222 patients eligible for inclusion. Overall, the average Caprini risk score was 4.78, which is between high risk (Caprini score 3-4) and highest risk (score 5-6). Of the patients, 37.8% were categorized as high risk and 55% of patients were categorized as highest risk. Despite this, only one patient had a thromboembolic event; he had a Caprini score of 3. Conclusions: In our cohort, 92.8% of patients were high risk or highest risk for VTE by Caprini risk score, while only a single patient had a thromboembolic event. Although the Caprini score is well accepted for quantifying thromboembolic risk in hospitalized patients, it appears to have limited applicability for patients undergoing urethroplasty, as it overestimates the risk of VTE in this population. Caprini score alone should not be used to guide treatment with chemoprophylaxis in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.